<DOC>
	<DOC>NCT01318941</DOC>
	<brief_summary>This study will describe the long-term safety and effectiveness, treatment patterns,and patient reported quality of life associated with ranibizumab treatment in routine clinical practice for all approved indication included in the local product label.</brief_summary>
	<brief_title>Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Papilledema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Adult patients, within age limits as defined by local regulations and local product label, who have previously been treated with, who are currently being treated with or initiating treatment with ranibizumab for any approved indication included in the local product label Willing and able to provide informed written consent personally or by legal proxy Simultaneous participation in a study that includes administration of any investigational drug or procedure Systemic or ocular treatment with any VEGF inhibitor other than ranibizumab in the 90 days prior to enrollment Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Ophthalmology, age-related macular degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, ranibizumab</keyword>
	<keyword>Ophthalmology</keyword>
	<keyword>Age-related macular degeneration</keyword>
	<keyword>Diabetic Macular Edema</keyword>
	<keyword>Retinal Vein Occlusion</keyword>
	<keyword>LUMINOUS</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>